Nordic Pancreatic Cancer Trial (NorPACT) - 1

Summary

This study evaluate the additional effect of adding chemotherapy prior to resection of a pancreatic head malignancy. The patients will be randomized into two groups; surgery first (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall survival after resection

Conditions

• Pancreatic Cancer

Interventions

DRUG

5-FU

Neoadjuvant treatment

DRUG

Oxaliplatine

Neoadjuvant treatment

DRUG

Irinotecan

Neoadjuvant treatment

PROCEDURE

Pancreatic surgery

All patients

DRUG

5-FU

Adjuvant treatment

DRUG

Oxaliplatine

Adjuvant treatment

DRUG

Irinotecan

Adjuvant treatment

Sponsors & Collaborators

• St. Olavs Hospital

  collaborator OTHER

• Haukeland University Hospital

  collaborator OTHER

• University Hospital of North Norway

  collaborator OTHER

• Sahlgrenska University Hospital

  collaborator OTHER

• Karolinska University Hospital

  collaborator OTHER

• University Hospital, Linkoeping

  collaborator OTHER

• Lund University Hospital

  collaborator OTHER

• Odense University Hospital

  collaborator OTHER

• Helsinki University Hospital, Finland

  collaborator UNKNOWN

• Norrlands University Hospital

  collaborator OTHER

• Helse Stavanger HF

  collaborator OTHER_GOV

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Knut Jorgen Labori, MD PhD · Oslo University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-09-30

Primary Completion

2022-12-22

Completion

2026-04-30

Countries

• Denmark
• Finland
• Norway
• Sweden

Study Locations